Attovia Therapeutics Stock (NASDAQ:ATTO)
Previous Close
$16.31
52W Range
$15.48 - $28.00
50D Avg
$20.55
200D Avg
$20.55
Market Cap
$697.52M
Avg Vol (3M)
$457.37K
Beta
-
Div Yield
-
ATTO Company Profile
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.